HopeStage
Back to all studies
CompletedNCT02892422

Long-Term Safety of Lu AF35700 for Adults With Schizophrenia

About this titleRead the official source — NCT02892422

Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Medication studyAges 18+Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Bellflower and 101 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 2016
Recruitment status
Completed
Enrollment listed in the registry
528
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada, Bulgaria, ...
Age range
Over 18 Years
Official registry ID
NCT02892422
Official title
Show the full official title

Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bellflower, United States · Costa Mesa, United States · Culver City, United States

74 more locations
  • Escondido, United States
  • Garden Grove, United States
  • National City, United States
  • Oceanside, United States
  • Orange, United States
  • San Bernardino, United States
  • Torrance, United States
  • Lauderhill, United States
  • Miami, United States
  • North Miami, United States
  • Oakland Park, United States
  • Atlanta, United States
  • Chicago, United States
  • Hoffman Estates, United States
  • Shreveport, United States
  • Flowood, United States
  • Las Vegas, United States
  • Berlin, United States
  • Fresh Meadows, United States
  • New York, United States
  • Rochester, United States
  • Staten Island, United States
  • Charlotte, United States
  • Norristown, United States
  • Austin, United States
  • Dallas, United States
  • Burgas, Bulgaria
  • Kazanlak, Bulgaria
  • Lovech, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Penticton, Canada
  • Brno, Czechia
  • Lnáře, Czechia
  • Prague, Czechia
  • Tallinn, Estonia
  • Durango, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Monterrey, Mexico
  • Bialystok, Poland
  • Lodz, Poland
  • Pruszcz Gdański, Poland
  • Torun, Poland
  • Wroclaw, Poland
  • Bucharest, Romania
  • Arkhangelsk, Russia
  • Gatchina, Russia
  • Moscow, Russia
  • Roshchino, Russia
  • Saint Petersburg, Russia
  • Yaroslavl, Russia
  • Belgrade, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Novi Kneževac, Serbia
  • Bratislava, Slovakia
  • Zlaté Moravce, Slovakia
  • Barcelona, Spain
  • Málaga, Spain
  • Oviedo, Spain
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Kiev, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Oleksandrivka, Ukraine
  • Poltava, Ukraine
  • Vinnitsa, Ukraine
  • Czechia
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Lu AF35700, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Did this study involve medication?

Yes. The study involved medication, including Lu AF35700.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies